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Abstract 
 
Over the past decade the field of lung cancer management has seen many developments. Coupled 
with an ageing population and increasing rates of co-morbid illness, the work-up for treatments with 
curative intent has become more complex and detailed. 
 
As well as improvements in imaging and staging techniques, developments in both surgery and 
radiotherapy may now allow patients who would previously have been considered unfit or not 
appropriate for treatment with curative intent to undergo radical therapies. 
 
This review article will highlight literature relating to investigation and staging techniques, together 
with assessments of fitness, with the aim of helping clinicians determine which are the most 
appropriate treatments for each patient. We also highlight areas where further research may be 
required. 
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Introduction 
 
It is well established that surgical resection offers patients the best chance of long term cure in early 
stage lung cancer1. Over the past decade there has been a successful drive to increase the number of 
patients undergoing resection, with the greatest increase in resection rates being noted in older age 
groups2, 3, 4,5.  The advent of Video Assisted Thoracoscopic Surgery (VATS) is further improving access 
for some who previously would not have been deemed suitable for surgical resection6,7. In addition 
to surgery, increasing numbers of patients who may not be eligible for surgical resection on grounds 
of fitness or disease extent are being offered radical radiotherapy or chemoradiotherapy with 
potential curative intent.  Although further work is required, Stereotactic Ablative Radiotherapy 
(SABR) may offer similar benefits to surgical resection in very early stage disease where the disease 
is localised to a small primary lesion8,9.  
 
As our population ages, the median age of those presenting with lung cancer is increasing and many 
coming forward for treatment have significant co-morbidities.  It is therefore imperative that we 
develop systems to ensure accurate assessments of physical health including cardiopulmonary 
reserve, alongside clear diagnostic and staging algorithms which allow as many patients as possible 
to be treated with curative intent4.  
 
In this review we outline the current evidence and guidelines available to assist with assessment and 
optimisation of lung cancer patients for treatment with curative intent.   
 
Although assessments for fitness and staging should be undertaken in parallel, for clarity we will 
address these issues separately. A holistic approach should be undertaken with an early assessment 
of fitness and performance status as this will begin to inform which treatment modalities may be 
possible for a given individual and depending upon disease extent, this will influence the most 
appropriate investigations (Figure 1). 
 
Diagnostic and Staging Investigations – imaging 
 
Accurate staging is essential for identifying the best treatment for each patient, leading to optimal 
treatment outcomes.  Over the last 15 years there has been a significant change in the approach to 
lung cancer staging with improvements in cross-sectional and functional imaging and a move away 
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from surgical staging techniques towards minimally invasive approaches such as endobronchial and 
endoscopic ultrasound.  
 
Chest radiograph 
Although most patients who present to a lung cancer service will have had a chest radiograph, the 
sensitivity and specificity of chest radiography for detecting lung cancer is low.  Approximately one 
quarter of patients with lung cancer have a “normal” chest radiograph at presentation10, 11.  In the 
presence of ‘red flag symptoms’ such as chronic cough, weight loss or haemoptysis, computed 
tomography is advised12. 
 
Computed tomography (CT) 
Modern multi-detector computed tomography allows images of the entire chest to be acquired in a 
single breath hold.  The standard staging scan should be an intravenous contrast enhanced, 
volumetric thin slice (≤ 1mm) CT which includes the chest and abdomen at least. Some units also 
advocate the extension of this imaging field to include the pelvis to aid assessment for bone 
metastases.  Post processing techniques allow multi-planar reconstructions in coronal and sagittal 
planes, which are often useful for planning surgical or radiotherapy treatments.  
 
Positron emission tomography/computed tomography (PET-CT) 
PET-CT has been shown to be superior to standard CT in the diagnosis and staging of lung cancer13-16. 
PET-CT is currently recommended by NICE as the preferred imaging modality for identifying both 
intra-thoracic and distant metastatic disease in lung cancer patients being considered for treatment 
with curative intent17. Reported sensitivity and specificity of PET-CT for detecting metastases in 
intrathoracic lymph nodes ranges from 85-89% and 84-94% respectively, compared with 70% and 
69% respectively for CT alone18.  In patients being considered for treatment with curative intent 
histological confirmation is often required to confirm the PET CT findings as false positive results 
may occur with inflammatory/infective conditions. Occult N2 disease has been described in up to 
16% of PET-CT negative nodes at the time of surgery with higher prevalence seen  in patients with 
PET-CT positive N1 nodes measuring >16 mm, central/RUL tumours, primary tumours with SUV >10 
and adenocarcinoma cell type19.  
 
Detection of unsuspected lymph node metastases (upstaging) depends on removal or sampling of 
lymph nodes, which is likely dependent on the completeness of the lymph node dissection and this 
strictly correlates with the surgical technique. Previous reports investigated the efficacy of lymph 
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node dissection during VATS and open lobectomy and found these were comparable20, 21, but recent 
data from The Society for Thoracic Surgeons (STS) database showed that nodal upstaging was 
significantly lower after lobectomy by VATS than after thoracotomy22.  
Current NICE guidelines recommend that mediastinal nodal sampling should be performed for all 
PET positive or PET negative nodes that measure > 1 cm in short axis. Normal sized mediastinal 
nodes that show no tracer uptake on PET-CT do not require further sampling17.  
 
 
Diagnostic and staging investigations – pathological confirmation 
 
Accurate pathological diagnosis is key to determining the optimal treatment for patients with lung 
cancer.  Current national clinical guidelines state that lung cancer should be histologically confirmed 
whenever practical and make clear recommendations around the sequence of investigations that 
should be used to diagnose and stage lung cancer17.  Patients being considered for treatment with 
curative intent should have CT and PET-CT performed prior to biopsies being undertaken. If, 
following these investigations, treatment with curative intent is still considered possible the biopsy 
approach chosen should be designed to provide as much diagnostic and staging information as 
possible. For instance, a small peripheral lesion staged T1aN0M0 by CT and PET-CT may require a CT 
guided needle biopsy only.  On the other hand a larger peri-hilar lesion staged T2bN2M0 by PET-CT 
may require mediastinal staging to clarify whether mediastinal nodes are involved, followed by a 
biopsy of the primary lesion if the mediastinal biopsy is negative for malignancy.   
 
Assessment of the mediastinum 
Accurate assessment of hilar mediastinal nodal involvement is becoming increasingly important in 
order to determine optimal treatment for patients being considered for treatment with curative 
intent.  Although surgical staging (predominantly cervical mediastinoscopy) has historically been 
considered the ‘gold standard,’ a number of trials have provided high-level evidence for the efficacy 
of Endobronchial Ultrasound (EBUS) leading to inclusion in national lung cancer staging guidelines. 
When combined with endoscopic ultrasound (EUS) the majority of the mediastinum can be assessed 
and combined EBUS/EUS has been shown to have equivalent accuracy to surgical staging23 and has 
been shown to be cost-effective24.  Although EBUS/EUS has reduced the need for surgical staging in 
lung cancer, cervical mediastinoscopy should still be considered following a ‘negative for malignancy’ 
result if a high degree of clinical suspicion of mediastinal nodal involvement remains25,26,27 and the 
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result will have a significant impact on management.  Although mediastinal staging has traditionally 
been considered in the context of staging prior to lung resection, it is increasingly realised that 
accurate hilar and mediastinal staging is important for patients being assessed for oncological 
treatments.  For instance EBUS/EUS can assist in mediastinal evaluation of radiotherapy field 
planning and with the increasing use of SABR, we are finding that EBUS is useful for assessing 
ipsilateral hilar and mediastinal nodes that are concerning on CT or PET-CT28.  
 
 
Assessment of fitness for surgical treatment 
Age 
Although age can be associated with an increased number of significant comorbidities, age alone 
should not exclude a patient from being considered for surgical treatment29, 30, 31.Approximately 30-
35% of candidates for surgical resection of lung cancer are aged >70 years32.  Several guidelines 
focussing on decision-making in elderly patients with lung cancer agree that assessments of 
cardiovascular and pulmonary fitness for surgery should be performed independent of age17, 31, 32, 34.  
 
Performance Status (PS) 
The Eastern Cooperative Oncology Group (ECOG) performance status and the Karnofsky 
performance status (KPS) are the most widely used tools to assess the functional status of cancer 
patients. Both tools describe the symptoms and functional abilities of patients with respect to their 
ambulatory status, and the ECOG and KPS scales have been shown to correlate well with one 
another both prior to and after treatment for lung cancer35. The ECOG score has been shown to have 
a slightly better prognostic predictive ability and is now more widely used in lung cancer assessment 
(table 1)35,37. Some studies have shown significant interpreter variability and when there is 
uncertainty around the PS of a patient that may alter treatment options, it is advisable to assess 
fitness further36.   
 
Cardiovascular evaluation prior to lung resection 
Many patients presenting with disease which is amenable to treatment with curative intent have 
underlying cardiopulmonary diseases secondary to cigarette smoking. In these patients the 
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perioperative risks of surgery and potential for long-term subsequent disability must be balanced 
against the potential benefit of curative treatment.  
There are currently three main sets of guidelines for the assessment of fitness of patients being 
considered for treatment of lung cancer with curative intent 32, 33,38. The British Thoracic Society 
(BTS) incorporates the guidelines from the  American College of Cardiology (ACC) and the American 
Heart Association (AHA) and suggests a focus on three major areas; the risk of post-operative cardiac 
event,  dyspnoea and the perioperative risk of mortality (see Figure 2)39. 
Myocardial infarction (MI) is a major cause of mortality in patients undergoing non-cardiac surgery. 
The prevalence of underlying coronary artery disease (CAD) in patients with lung cancer is between 
11% and 17%, and the risk of myocardial infarction or death in all patients undergoing lung resection 
surgery is estimated to be 1-5% 39, 40. Limitations in exercise tolerance secondary to CAD can be 
masked by lung disease and it is therefore recommended that careful assessment is made39. In 
patients who are known to have had a recent myocardial infarction, NICE recommend that surgery 
should be avoided for at least 30 days17. 
Preoperative evaluation of cardiovascular disease should include focused history-taking, 
examination, and 12-lead electrocardiography (ECG), as well as calculation of the Thoracic Revised 
Cardiac Risk Index (ThRCRI) 36. The ThRCRI was developed in recognition that the original Revised 
Cardiac Risk Index (RCRI) was inaccurate at predicting cardiovascular complications in patients 
undergoing lung resection40, 42. The ThRCRI risk score incorporates multiple patient factors (see table 
2) and the extent of planned lung resection in order to stratify patients into risk categories for 
developing cardiovascular complications (table 3). It has been validated both in single centre studies 
and in a multicentre review43, 44,45and current guidelines recommend it for stratification of risk of 
postoperative cardiovascular complications following lung resection surgery32, 33, 38 (figure 3).  
Pre-operative non-invasive testing is aimed primarily at the detection of left ventricular dysfunction, 
myocardial ischaemia, and significant valvular heart disease. While routine pre-operative 
echocardiography is not necessary in all patients, it is reasonable in patients undergoing major 
intrathoracic surgery (e.g. pneumonectomy), and in patients with a history of pre-existing 
cardiovascular disease46.  If cardiac conditions are discovered or suspected, or patients have an 
ThRCRI score >2, then patients should be assessed by a cardiologist; in these cases functional 
imaging for evidence of reversible ischaemia is warranted as patients may require preoperative 
optimisation (2014 ESC guidelines)38, 46.  
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Patients with identified CAD should have their anti-anginal medications optimised; current evidence 
is in favour of continuing beta blockade in established patients, along with antiplatelet therapy and 
statins. However, it is not recommended to routinely initiate beta blockade in patients who are 
treatment naïve immediately prior to surgery as this may increase the risk of cerebrovascular 
accident despite offering some protection against non-fatal MI45, 47. Patients who may benefit from 
the introduction of beta-blockers preoperatively are those with a high number of cardiac risk factors, 
and those with known ischaemic heart disease or myocardial ischaemia 48.  
No significant increase in peri-operative major cardiac events has been demonstrated in patients 
with inducible ischaemic affecting less than 20% of the total left ventricular myocardium49. However, 
in the presence of a significant ischaemia burden, particularly if symptoms of angina exhibit an 
unstable or crescendo pattern, revascularization prior to surgery should be considered as it may 
reduce the risk of postoperative MI and death38, 50. Cardiac revascularisation of CAD with myocardial 
ischaemia is therefore recommended in cases where the surgical resection can be delayed safely for 
this to take place46, 48.  
 
Thoracoscore 
The National Lung Cancer Audit 2011 reported the 30-day mortalities for lobectomy and 
pneumonectomy procedures to be 2.3% and 7.0% respectively38, 51, 52.  Given the number of variables 
that impact on an individual’s risk of dying in the postoperative period, holistic scoring systems are 
required in helping predict which patients are at greatest risk.   
The BTS and NICE guidelines recommend the Thoracoscore for predicting perioperative hospital 
mortality17,38.  Thoracoscore incorporates the effect of nine variables to give a pre-operative 
prediction of patient mortality; age, gender, ASA classification, WHO performance status, Medical 
Research Council dyspnoea score, priority of surgery, procedure class, diagnosis and comorbidity 
score53, 54.  
For patients undergoing pneumonectomy, some recent studies have indicated that it may 
overestimate mortality in high risk groups, whilst underestimating risk in low risk groups55. When 
applied to a large UK-based population it appeared to generally overestimate mortality56, 57. 
Therefore, although Thoracoscore remains the most holistic and validated scoring system, it should 
be interpreted with caution when deciding whether or not to offer surgical treatment for lung 
cancer.  
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Spirometry, diffusion capacity and predicted postoperative (PPO) lung function 
Basic spirometry and diffusion capacity are commonly used to initiate assessment of respiratory 
function prior to surgery. Spirometry alone is a less sensitive predictor of postoperative mortality 
than diffusion capacity and for this reason should not be used in isolation for assessment38, 58, 59.  
Predicted postoperative (PPO) FEV1 or PPO TLCO for patients who are being considered for 
lobectomy is usually calculated by dividing the preoperative lung function by the total number of 
preoperative bronchopulmonary segments (usually nineteen), and then multiplying it by the number 
of segments that will remain postoperatively17,60. This is a crude measurement as these calculations 
cannot take into account the functionality of each segment. 
The 2010 BTS guidelines suggest that there is a poor clinical correlation between PPO lung function 
(PPO FEV1 and PPO TLCO) and the postoperative quality of life score38, 61, 62. One study found that 
when a lower PPO FEV1 threshold of 30% was applied (rather than previous minimum of 40%), 
patients continued to have acceptable postoperative mortality rates (4%) and better than predicted 
postoperative lung function63.   
The use of PPO FEV1 is further limited because some patients can benefit from a lung volume 
reduction surgery effect32, 64, 65.  In patients with emphysema, reduction in the volume of 
emphysematous parenchyma can improve lung function, and therefore in patients with lung cancer 
and concomitant emphysema the postoperative FEV1 can be underestimated66.  Conversely, PPO 
FEV1 can substantially overestimate the actual FEV1 observed in the early postoperative phase when 
most complications occur67, 68.  
Patients and physicians may be concerned about the prospect of potentially life-altering dyspnoea 
after lung resection.  The BTS now recommends that rather than using a firm cut-off for the lower 
limit of PPO FEV1, a discussion with the patient about potential risks is considered38.  This approach 
is supported by the current NICE guideline, which advises that patients with a PPO FEV1 or PPO TLCO 
below the recommended lower limit of 30% still be considered for surgical treatment if they accept 
the risk of postoperative breathlessness and complications17.  
 
Exercise testing; 6-minute walk, shuttle tests and cardiopulmonary exercise testing 
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The shuttle and the 6-minute walk tests deliver an objective measure of exercise capacity.  The 6 
minute walk test asks a patient to walk as far as possible within 6 minutes and enables them to rest 
as needed. Results correlate well with VO2 max (maximal oxygen consumption measured by 
cardiopulmonary exercise testing), but it is debatable whether it enables prediction of postoperative 
outcomes33, 69, 70.  
The shuttle test requires the patient to walk back and forth between fixed points at increasing speed 
until they are unable to maintain the required speed. This method has been shown to correlate well 
with the VO2 max (25 shuttles correlating to a VO2 max of 10 mL/kg-1/min-1) but may not 
differentiate patients who later develop postoperative complications71, 72.  The current BTS 
guidelines advocate the use of the shuttle test in patients with borderline lung function testing; 
where the patient manages >400m during the test this can be used as a marker of good preoperative 
function and only patients who fail this test or have other risk factors will require formal 
cardiopulmonary exercise testing (CPET)33,38. 
CPET is a non-invasive test of exercise capacity, and is recommended for assessment of patients with 
PPO FEV1 or PPO TLCO <30% predicted32, and for patients with a moderate-high risk of 
postoperative breathlessness38.  Patients exercise on a treadmill or an exercise bike, with continuous 
monitoring of multiple parameters including VO2 max. As well as being a highly reproducible 
method of quantifying exercise capacity, CPET can often enable clinicians to establish the underlying 
cause of the limitations and to treat or optimise them where possible.  Current guidelines 
recommend using VO2 max >15mL/kg/min as a marker of good function38, and suggest that a VO2 
max of >20ml/kg/min (or >75% predicted) can be used as a cut off as a safe measure for patients 
who are being considered for pneumonectomy.  Conversely a VO2 max <10ml/kg/min (or <35% 
predicted) indicates high risk for any lung resection (see figure 4)33. 
 
Ventilation/perfusion scans 
Quantitative ventilation-perfusion scanning enables an assessment of the percentage function of 
each lung and individual zones, and is one of the most commonly used methods of assessing 
patients prior to pneumonectomy.  Scintigraphy is less commonly adopted in patients undergoing 
lobectomy because it offers a picture of the regional distribution (upper/mid/lower zones) rather 
than the actual contribution of each individual lobe or segment.  
Ventilation-perfusion scintigraphy enables a calculation of the PPO FEV1 or TLCO based on the 
functional activity of the remaining lung parenchyma and the preoperative FEV1 or TLCO.  Both 
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ventilation and perfusion scintigraphy have been shown to provide high quality predictions of PPO 
lung function although there seems to be no additional benefit in performing both73,74,75.  The 
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (2011) advise that 
patients with borderline lung function testing have ventilation/perfusion scintigraphy prior to 
pneumonectomy33.  
 
Assessment for curative, non-surgical treatments 
 
Although surgery remains the gold standard treatment for patients with early stage lung cancer, 
those with good PS (performance status), deemed to have non-operable disease or who decline 
surgery should still be considered for curative treatments with radiotherapy or chemoradiotherapy. 
Generally patients with localised disease who are PS 0-1, without significant co-morbidities are 
suitable. Some PS 2 patients may also be suitable but careful selection and counselling are required. 
In very early stage, localised disease, some PS 3 patients can be considered for SABR therapy 
dependent on the cause of their limited function.   
Patients with stage I-III NSCLC not suitable for surgery should be assessed by a Clinical Oncologist 
specialising in thoracic oncology17. Patients with limited stage SCLC and good performance status 
should also be considered for combination chemoradiotherapy17. Non-surgical patients with stage I-
II NSCLC should be offered curative radiotherapy with various fractionation regimes including 
stereotactic ablative radiotherapy (SABR), continuous hyperfractionated accelerated radiotherapy 
(CHART) or conventionally fractioned radical radiotherapy undertaken over a 4 - 6.5 week period.  In 
addition patients with stage II-III disease should also be considered for chemoradiotherapy providing 
survival benefit is balanced with the risk of toxicity. 
 
Radiotherapy with curative intent  
Patients are required to lie in a semi-recumbent position and maintain this for the duration of their 
radiotherapy treatments. Each can take greater than 30 minutes to complete and patients may 
require supports, analgesics or oxygen in order to help maintain comfort and position. 
Effective radiotherapy must target tumours whist protecting surrounding organs at risk (OARs).  
There are no current guidelines demonstrating a “safe” lower limit of lung function for radiotherapy 
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and those with poor lung function should still be considered for radiotherapy provided the tumour 
volume is small17, 33. However, given the risk of radiation induced pneumonitis, we would advocate 
that patients with limited physiological reserve should be carefully assessed and counselled prior to 
treatment. It is our experience that patients with an FEV1 as low as 0.4L can be considered for SABR 
therapy provided the disease volume is low and adequate counselling of the patient is undertaken. 
Pulmonary fibrosis is typically considered to be a contraindication due to the potential of 
accelerating the inflammatory process leading to worsening of respiratory function28. There is some 
variation between oncologists regarding radiotherapy and in various subtypes of pulmonary fibrosis 
although there is consensus that this modality of treatment is contraindicated in Usual Interstitial 
Pneumonia (UIP).  
The use of SABR to treat small (< 5cm) peripheral, node negative lesions is increasing. When 
planning for SABR, tumours must be > 2 cm away from the bifurcation of the second order bronchus 
(the ‘no fly’ zone) and consideration must be given to OARs which include the spinal cord, heart, 
oesophagus and ipsilateral brachial plexus.   
 
Chemoradiotherapy 
Platinum based chemotherapy as part of chemoradiotherapy is the mainstay of treatment. Cisplatin 
or carboplatin are the two drugs most commonly used, in combination with one other cytotoxic 
agent such as etoposide, vinorelbine or paclitaxel.  Chemotherapy can be given sequentially or 
concurrently with radiation. Cisplatin is the most studied agent but is nephrotoxic meaning dose 
reductions are advisable in patients with a glomerular filtration rates (GFR) <60ml/min. At lower 
GFRs, substitution with carboplatin is required and platinum based chemotherapies are 
contraindicated in severe renal impairment. If considering cisplatin, a full assessment of renal 
function is required before, during and after treatment76. Adequate hydration including forced 
diuresis is required and patients must be able to tolerate a large intravenous fluid load. Other 
significant toxicities include neuropathy and high tone hearing loss which needs to be taken into 
consideration in those with these pre-existing co-morbidities. 
A systematic review demonstrated the benefits of concurrent chemo-radiation, radiotherapy alone 
and sequential chemoradiotherapy, but noted increased toxicity including radiation oesophagitis 
meaning patient selection has to be an important consideration in deciding those who will most 
benefit77. 
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Optimisation of respiratory function 
 
Smoking cessation 
Smoking cessation is always recommended in patients with lung malignancy and the majority of 
patients presenting with lung cancer will be either current smokers or ex-smokers.  Current 
guidelines recommend that smoking cessation be advocated in patients being considered for surgical 
resection of lung cancer17, 32, 33. There is also increasing evidence that smoking can be detrimental to 
the efficacy of systemic chemotherapy agents used to treat lung cancer, by inducing enzymes which 
metabolise these medicines78, and can lead to increased rates of treatment-related pneumonitis in 
patients receiving definitive radiotherapy79. In addition, smoking cessation at the time of lung cancer 
diagnosis is likely to positively impact future respiratory health, reducing the likelihood of disease 
recurrence or development of further cancers80.  
To date, there are no randomised controlled studies examining the impact of smoking cessation 
prior to surgery81. However, multiple studies have shown that patients with a smoking history 
(current or ex-smokers) have increased postoperative mortality and morbidity compared to never-
smokers82-86.  One retrospective cohort study found that preoperative smoking cessation may reduce 
the risk of postoperative pulmonary complications, but for maximal benefit cessation should occur 
at least four weeks prior to surgery87. There are substantial limitations in many of the available 
studies into the timing of smoking cessation in lung cancer patients considered for lung resection, 
and current NICE guidelines (2011) advise that surgical treatment of lung cancer should not be 
postponed to allow patients to stop smoking17.  
Although some methods of promoting smoking cessation have been found to have limited 
effectiveness (e.g. self-help information provision or being advised to stop smoking as part of a 
wider consultation) there is growing evidence that pharmacological interventions and more 
intensive smoking cessation therapy (such as formal cessation counselling) improve the likelihood of 
successful cessation85, 88.     
Over recent years there has been increasing interest in the role of new adjuncts such as electronic 
cigarettes (also known as e-cigarettes) in smoking cessation.  The Royal College of Physicians have 
published a report exploring concerns around the safety of e-cigarettes and provided reassurance 
that long-term use of e-cigarettes is unlikely to exceed 5% of the harm from cigarette smoking89.  
The efficacy of e-cigarettes in smoking cessation also remains an area of contention.  A randomised 
controlled trial published in 2013 suggested that e-cigarettes might improve abstinence from 
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smoking compared to nicotine patches or placebo, but the results were not statistically significant as 
the study was underpowered; researchers had been anticipating higher overall abstinence rates90.  A 
recent review and meta-analysis of the current use of e-cigarettes suggested that patients currently 
choosing to use e-cigarettes did not have increased rates of smoking cessation compared to other 
patients91. Certainly further randomised controlled studies evaluating the efficacy of e-cigarettes in 
smoking cessation are required.    
 
Medical Treatment of underlying lung disease 
Lung cancer often co-exists with COPD and/or pulmonary fibrosis and managing physicians should be 
alert to the possibility of improving lung function testing and performance status through medical 
therapy. 
There is debate as to whether COPD is an independent risk factor for lung cancer or whether the 
relationship between the two diseases is simply due to a common pathogenic trigger92,93,94. Patients 
with COPD should have their condition optimised with inhaled therapy which will likely include 
combination inhalers (steroid and beta-2 agonist preparations) and anti-cholinergic therapies.  
Inhaled therapies have their actions on airway airflow obstruction and are generally ineffective for 
treating purely parenchymal disease.  In some cases where a cancer is found within an area of 
severe emphysema, surgery can still be considered as a patient may benefit from a lung volume 
reduction effect94. Assessment for this should be undertaken with a surgeon experienced in lung 
volume reduction and cancer treatments. COPD does not usually preclude radiotherapy treatment. 
As radiotherapy is typically contraindicated in patients with pulmonary fibrosis, sublobar resections 
such as wedge resections or segmentectomy procedures may be more appropriate as they will have 
a less deleterious effect on underlying lung reserve.  Prior to surgery, gastro-oesophageal reflux 
disease should be treated and potentially reversible causes of inflammatory disease should be 
identified and treated. 
  
Pulmonary rehabilitation  
Pulmonary rehabilitation combines a course of education and exercises that aims to improve lung 
function and symptoms in patients with long-term respiratory conditions95.  Postoperative 
pulmonary complications are the main cause of mortality in patients who have undergone surgical 
resection of lung cancer96. Pulmonary rehabilitation has been proven to be effective in candidates 
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for lung-volume reduction surgery and for patients undergoing lung transplantation97,98,99. 
International guidelines have acknowledged that pulmonary rehabilitation may have a role in 
reducing complications for lung cancer resection patients.  
A study performed by Gao et al demonstrated that patients receiving pulmonary rehabilitation prior 
to lobectomy had reduced postoperative complications and shorter hospital stays than those not 
receiving pulmonary rehabilitation100.  Further studies have also suggested benefits in the 
postoperative functional status of patients receiving preoperative pulmonary rehabilitation, with 
increased VO2 max and a possible reduction in hospital length of stay following surgical resection101.  
The exercise capacity of patients undergoing lung resection surgery is commonly reduced in the 
postoperative period, although many patients gradually regain function over the following year64.  
Several studies have shown improvement in dyspnoea (measured with the Borg scale), improved 
FEV1 and FVC, and 6 minute walk distance with postoperative pulmonary rehabilitation 102,103. 
Although promising, these studies investigated low numbers of patients with differing treatment 
methodologies.  A large prospective randomised trial found that although 6 minute walk distance 
was increased in patients undergoing postoperative pulmonary rehabilitation, the quality of life of 
the group was not significantly different104.  They also found that commencing pulmonary 
rehabilitation soon after surgery led to increased reporting of postoperative pain, and in view of this 
the authors recommended delaying the start of pulmonary rehabilitation to 3-4 months post 
resection.  Overall, the evidence suggests that there might be some benefit to preoperative and 
postoperative pulmonary rehabilitation in lung resection patients.  
 
Conclusion 
With an aging population and increasing disease complexity, the work-up, staging and physiological 
assessments of patients with lung cancer is becoming increasingly challenging. The patient being 
considered for treatment with curative intent is required to undergo multiple investigations to 
establish their suitability for treatments.  Lung cancer management requires the integration of a 
well-functioning multidisciplinary team in order to achieve optimal results.  Management planning 
should be considered in the context of not only treatment of the disease but also the short- and 
long-term sequelae of treatments, with reduced emphasis placed upon absolute physiological cut-
offs and increased value placed upon discussion of risks with individual patients.  
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Figures 
 
Figure 1- Overview of investigation pathway for patients under consideration for treatment with 
curative intent.
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Figure 2- Tripartite risk assessment from the American College of Cardiology (ACC) and American 
Heart Association (AHA) - adapted from BTS 2010 guidelines38, 39.  
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Figure 3- Adapted from Chest guidelines 2013, originally derived from ERS/ESTS clinical guidelines on 
fitness for lung resection in lung cancer patients32,33.  
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Figure 4- Lung Function physiologic evaluation resection algorithm- adapted from algorithm by 
Brunelli et al 201332. 
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 Tables 
Table 1- ECOG performance status, as published by the Eastern Cooperative Oncology Group 198237 
 ECOG performance status 
0 Fully active, able to perform all pre-disease activities without 
restriction 
1 Restricted in physically strenuous activity but ambulatory and able to 
carry out work of a light or sedentary nature 
2 Ambulatory and capable of all self-care but unable to carry out work 
activities; up and about more than 50% of waking hours  
3 Capable of only limited self-care; confined to bed or chair for more 
than 50% of waking hours  
4 Completely disabled; cannot carry out any self-care; totally confined to 
bed or chair 
 
Table 2- ThRCRI scoring system. Table adapted from Brunelli et al 201040. 
 
 
Table 3- Risk of major cardiac complications in patients undergoing major lung sections (lobectomy 
or pneumonectomy). Table adapted from Brunelli et al 201040. 
Risk category ThRCRI score Major cardiac complications 
(% patients) 
A 0 1.5 
B 1-1.5 5.8  
C 2-2.5 19 
D >2.5 23 
 
Risk factor Score 
Creatinine >=2mg/dl 
(>177µmol/L), or on renal 
replacement therapy 
1 
Coronary artery disease 1.5 
Cerebrovascular disease 1.5 
Pneumonectomy 1 
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